GMAB ▲ +0.8% - Genmab A/S $GMAB Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer 04-OCT-2026 11:01 AM ET